

Hemodynamic evaluation of the addition of isosorbide- cirrhotic patients with insufficient response to the β -bl

Hepatology

26, 34-39

DOI: [10.1002/hep.510260105](https://doi.org/10.1002/hep.510260105)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Rational design and functional expression of a constitutively active single-chain NS4A-NS3 proteinase. <i>Folding & Design</i> , 1998, 3, 433-441.	4.5	14
2	10-year follow-up after interferon- α therapy for chronic hepatitis C. <i>Hepatology</i> , 1998, 28, 1121-1127.	3.6	275
3	Duplex-Doppler evaluation of the effects of propranolol and isosorbide-5-mononitrate on portal flow and splanchnic arterial circulation in cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 1998, 12, 475-481.	1.9	8
4	Hepatitis C. <i>Lancet</i> , The, 1998, 351, 351-355.	6.3	306
5	Doppler sonography and hepatic vein catheterization in portal hypertension: assessment of agreement in evaluating severity and response to treatment. <i>Journal of Hepatology</i> , 1998, 28, 622-630.	1.8	66
6	Systemic and Portal Hemodynamic Response to Propranolol in Patients with Portal Hypertension Due to Hepatitis C Virus. <i>Medical Principles and Practice</i> , 1998, 7, 187-191.	1.1	0
7	Pharmacologic Prevention of Rebleeding. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 1999, 9, 301-310.	0.6	3
8	Influence of Pharmacological Agents on Portal Hemodynamics: Basis for Its Use in the Treatment of Portal Hypertension. <i>Seminars in Liver Disease</i> , 1999, 19, 427-438.	1.8	92
9	Urinary Porphyrin Excretion in Hepatitis C Infection. <i>Clinical Chemistry and Laboratory Medicine</i> , 1999, 37, 799-804.	1.4	3
10	Fluorine-18 Fdg Positron Emission Tomography for Imaging of Hepatocellular Carcinoma. <i>American Journal of Gastroenterology</i> , 1999, 94, 3314-3319.	0.2	240
11	Doppler evaluation of the effects of pharmacological treatment of portal hypertension. <i>Ultrasound in Medicine and Biology</i> , 1999, 25, 923-932.	0.7	9
12	Hepatocellular carcinoma after sustained response to interferon in non-cirrhotic hepatitis C: Flaws in the cure, or a clue to the flaws?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1999, 14, 833-837.	1.4	15
13	Chromosomal aberrations in human hepatocellular carcinomas associated with hepatitis C virus infection detected by comparative genomic hybridization. <i>British Journal of Cancer</i> , 1999, 80, 2034-2039.	2.9	74
14	The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the united states. <i>Hepatology</i> , 1999, 29, 1311-1316.	3.6	249
15	Carvedilol, a new nonselective beta-blocker with intrinsic anti-alpha1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis. <i>Hepatology</i> , 1999, 30, 79-83.	3.6	158
16	Clinical features of hepatitis C-infected patients with persistently normal alanine transaminase levels in the southwestern United States. <i>Hepatology</i> , 1999, 30, 1307-1311.	3.6	127
17	Prophylaxis of Hepatitis C with Intramuscular Immunoglobulin. <i>BioDrugs</i> , 1999, 12, 291-300.	2.2	5
18	Acute and chronic haemodynamic and renal effects of carvedilol in patients with cirrhosis. <i>Journal of Hepatology</i> , 1999, 30, 479-484.	1.8	66

#	ARTICLE	IF	CITATIONS
19	Risk of hepatitis C virus transmission to surgeons and nurses from infected patients: model-based estimates in France. <i>Journal of Hepatology</i> , 1999, 30, 765-769.	1.8	32
20	Rising Incidence of Hepatocellular Carcinoma in the United States. <i>New England Journal of Medicine</i> , 1999, 340, 745-750.	13.9	3,008
21	β-Catenin Mutations Are Frequent in Human Hepatocellular Carcinomas Associated with Hepatitis C Virus Infection. <i>American Journal of Pathology</i> , 1999, 155, 1795-1801.	1.9	261
22	Influence of Chronic Alcohol Abuse on Hepatitis C Virus Replication. <i>Digestive Diseases</i> , 2000, 18, 168-171.	0.8	26
23	Long-term results of a clinical trial of nadolol with or without isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis. <i>Hepatology</i> , 2000, 31, 324-329.	3.6	127
24	Activation of nuclear factor κB in hepatitis C virus infection: Implications for pathogenesis and hepatocarcinogenesis. <i>Hepatology</i> , 2000, 31, 656-664.	3.6	184
25	Liver transplantation. <i>Liver Transplantation</i> , 2000, 6, 122-135.	1.3	97
26	Erythrocyte protoporphyrins in hepatitis C viral infection. <i>Clinical Biochemistry</i> , 2000, 33, 387-391.	0.8	12
27	Treatment of chronic hepatitis C virus infection in patients with cirrhosis. <i>Journal of Viral Hepatitis</i> , 2000, 7, 327-334.	1.0	21
28	A prospective study of interferon therapy modified by pre-treatment viral load in cirrhotic patients. <i>Liver</i> , 2000, 20, 271-280.	0.1	5
29	Coinfection with HIV and HCV: More Questions than Answers?. <i>Pharmacotherapy</i> , 2000, 20, 1499-1507.	1.2	11
30	Distribution of HCV genotypes among risk groups in Serbia. <i>European Journal of Epidemiology</i> , 2000, 16, 949-954.	2.5	16
31	Natural history of hepatitis C: Its impact on clinical management. <i>Hepatology</i> , 2000, 31, 1014-1018.	3.6	249
32	Predictive value of the variceal pressure response to continued pharmacological therapy in patients with cirrhosis and portal hypertension. <i>Hepatology</i> , 2000, 31, 1061-1067.	3.6	158
33	The Hemodynamic Response to Medical Treatment of Portal Hypertension as a Predictor of Clinical Effectiveness in the Primary Prophylaxis of Variceal Bleeding in Cirrhosis. <i>Hepatology</i> , 2000, 32, 930-934.	3.6	224
35	Investigation on hepatitis C and B virus infection in carcinoma of the extrahepatic bile duct in China. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2000, 12, 165-171.	0.7	0
36	HepatozellulÄres Karzinom. <i>Onkologe</i> , 2000, 6, 292-300.	0.7	0
37	Hepatectomy for hepatitis B-, hepatitis C-, and dual hepatitis B- and C-related hepatocellular carcinoma in Taiwan. <i>Journal of Hepato-Biliary-Pancreatic Surgery</i> , 2000, 7, 265-269.	2.0	21

#	ARTICLE	IF	CITATIONS
38	Cellular immune response in HCV infection. <i>Journal of Gastroenterology</i> , 2000, 35, 881-889.	2.3	6
39	Organic nitrates for prevention of oesophageal varices bleeding and re-bleeding. <i>The Cochrane Library</i> , 2000, , .	1.5	1
40	Hepatitis C Virus NS5A Protein Modulates Transcription through a Novel Cellular Transcription Factor SRCAP. <i>Journal of Biological Chemistry</i> , 2000, 275, 7184-7188.	1.6	76
41	Comparison of Portal Vein Velocity and The Hepatic Venous Pressure Gradient in Assessing The Acute Portal Hemodynamic Response To Propranolol in Patients With Cirrhosis. <i>American Journal of Gastroenterology</i> , 2000, 95, 2905-2909.	0.2	31
42	Somatostatin plus isosorbide 5-mononitrate versus somatostatin in the control of acute gastro-oesophageal variceal bleeding: a double blind, randomised, placebo controlled clinical trial. <i>Gut</i> , 2000, 46, 127-132.	6.1	13
43	Pretransplantation Surveillance for Possible Hepatocellular Carcinoma in Patients with Cirrhosis: Epidemiology and CT-based Tumor Detection Rate in 430 Cases with Surgical Pathologic Correlation. <i>Radiology</i> , 2000, 217, 743-749.	3.6	178
44	Neuropsychiatric Symptoms Associated With Hepatitis C and Interferon Alpha: A Review. <i>American Journal of Psychiatry</i> , 2000, 157, 867-876.	4.0	405
45	The natural history of HCV in a cohort of haemophilic patients infected between 1961 and 1985. <i>Gut</i> , 2000, 47, 845-851.	6.1	157
46	Significant differences in serum activities of matrix metalloproteinase-2 and -9 between HCV- and HBV-infected patients and carriers. <i>Clinica Chimica Acta</i> , 2000, 294, 157-168.	0.5	26
47	VIRAL HEPATITIS. <i>Clinics in Liver Disease</i> , 2000, 4, 849-877.	1.0	11
50	Complications of cirrhosis. I. Portal hypertension. <i>Journal of Hepatology</i> , 2000, 32, 141-156.	1.8	416
51	Long-acting nitrates in portal hypertension: to be or not to be?. <i>Digestive and Liver Disease</i> , 2001, 33, 205-211.	0.4	9
52	Endoscopic Ligation Compared with Combined Treatment with Nadolol and Isosorbide Mononitrate to Prevent Recurrent Variceal Bleeding. <i>New England Journal of Medicine</i> , 2001, 345, 647-655.	13.9	335
53	Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. <i>American Journal of Gastroenterology</i> , 2001, 96, 179-183.	0.2	62
54	No Direct Role for Epstein-Barr Virus in American Hepatocellular Carcinoma. <i>American Journal of Pathology</i> , 2001, 159, 1287-1292.	1.9	22
55	Natural history of chronic hepatitis C: Identifying a window of opportunity for intervention. <i>Disease-a-Month</i> , 2001, 47, 593-609.	0.4	1
56	Impact of infectious diseases on women's health: 1776â€“2026. <i>Obstetrics and Gynecology</i> , 2001, 97, 1019-1023.	1.2	5
57	CURRENT AND FUTURE THERAPIES OF HEPATITIS C. <i>Clinics in Liver Disease</i> , 2001, 5, 335-360.	1.0	19

#	ARTICLE	IF	CITATIONS
58	Treatment of Hepatitis C with Milk Thistle?. <i>Journal of Herbal Pharmacotherapy: Innovations in Clinical and Applied Evidence-based Herbal Medicinals</i> , 2001, 1, 79-90.	0.1	3
59	Prevention of Hepatocellular Carcinoma in Chronic Liver Disease: Molecular Markers and Clinical Implications. <i>Digestive Diseases</i> , 2001, 19, 338-344.	0.8	4
60	Primary prophylaxis of variceal bleeding in cirrhosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2001, 13, 349-358.	0.8	16
61	Stellenwert der Lebertransplantation beim hepatozellulären Karzinom. <i>Onkologie</i> , 2001, 7, 1296-1304.	0.7	0
62	A drug therapy for the prevention of variceal haemorrhage. <i>Alimentary Pharmacology and Therapeutics</i> , 2001, 15, 291-310.	1.9	20
63	Hepatitis C viral clearance and antibody reactivity patterns in persons with haemophilia and other congenital bleeding disorders. <i>Haemophilia</i> , 2001, 7, 568-574.	1.0	35
64	Hepatitis C in clinical practice. <i>Journal of Internal Medicine</i> , 2001, 249, 111-120.	2.7	15
65	Hepatitis C virus core protein promotes cell proliferation through the upregulation of cyclin E expression levels. <i>Liver</i> , 2001, 21, 137-142.	0.1	48
66	Expression of c-myc promoter binding protein (MBP-1), a novel eukaryotic repressor gene, in cirrhosis and human hepatocellular carcinoma. <i>Digestive Diseases and Sciences</i> , 2001, 46, 563-566.	1.1	3
67	Natural history of chronic hepatitis C: Identifying a window of opportunity for intervention. <i>Translational Research</i> , 2001, 137, 146-154.	2.4	1
68	Hepatitis C Virus NS5A Physically Associates with p53 and Regulates p21/waf1 Gene Expression in a p53-Dependent Manner. <i>Journal of Virology</i> , 2001, 75, 1401-1407.	1.5	237
70	Serum 90K/MAC-2BP Glycoprotein in Patients with Liver Cirrhosis and Hepatocellular Carcinoma: a Comparison with Î±-Fetoprotein. <i>Clinical Chemistry and Laboratory Medicine</i> , 2001, 39, 961-5.	1.4	39
71	Hemangioma in the Cirrhotic Liver: Diagnosis and Natural History. <i>Radiology</i> , 2001, 219, 69-74.	3.6	145
72	Effects of different octreotide dosages on splanchnic hemodynamics and glucagon in patients with TIPS. <i>American Journal of Gastroenterology</i> , 2001, 96, 2218-2224.	0.2	11
73	Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. <i>American Journal of Gastroenterology</i> , 2001, 96, 179-183.	0.2	215
74	Human hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF-Î±B. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 9599-9604.	3.3	555
75	Structure-Based Mutational Analysis of the Hepatitis C Virus NS3 Helicase. <i>Journal of Virology</i> , 2001, 75, 8289-8297.	1.5	65
76	Hepatocellular Carcinoma in Noncirrhotic Liver: CT, Clinical, and Pathologic Findings in 39 U.S. Residents. <i>Radiology</i> , 2002, 222, 89-94.	3.6	91

#	ARTICLE	IF	CITATIONS
77	Influence of age on clinical presentation, therapeutic options, and prognosis in anti-HCV positive cirrhotic patients with hepatocellular carcinoma. <i>Age and Ageing</i> , 2002, 31, 457-462.	0.7	11
78	Hepatitis C Virus Subgenomic Replicons Induce Endoplasmic Reticulum Stress Activating an Intracellular Signaling Pathway. <i>Journal of Virology</i> , 2002, 76, 7453-7459.	1.5	232
79	Empirically Calibrated Model of Hepatitis C Virus Infection in the United States. <i>American Journal of Epidemiology</i> , 2002, 156, 761-773.	1.6	112
80	Update on Treatment of Variceal Hemorrhage. <i>Digestive Diseases</i> , 2002, 20, 134-144.	0.8	6
81	Combined therapy for secondary prophylaxis of variceal rebleeding?. <i>American Journal of Gastroenterology</i> , 2002, 97, 2134-2136.	0.2	1
82	Primary prophylaxis of variceal hemorrhage: A randomized controlled trial comparing band ligation, propranolol, and isosorbide mononitrate. <i>Gastroenterology</i> , 2002, 123, 735-744.	0.6	171
84	Epidemiology and Clinical Presentation of Hepatocellular Carcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 2002, 13, S169-S171.	0.2	86
85	Imaging Evaluation of Hepatocellular Carcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 2002, 13, S173-S183.	0.2	28
86	Hepatitis C virus infection in patients on renal replacement therapy. <i>Hong Kong Journal of Nephrology</i> , 2002, 4, 3-12.	0.0	0
87	Higher prevalence of anti-HCV antibodies among HIV-positive compared to HIV-negative inhabitants of Addis Ababa, Ethiopia. <i>Journal of Medical Virology</i> , 2002, 68, 12-17.	2.5	60
88	Basal replication of hepatitis C virus in nude mice harboring human tumor. <i>Journal of Medical Virology</i> , 2002, 66, 312-319.	2.5	7
89	Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis. <i>Hepatology</i> , 2002, 36, 1367-1373.	3.6	121
90	Cytokine serum levels in patients with chronic HCV infection. <i>Journal of Clinical Laboratory Analysis</i> , 2002, 16, 40-46.	0.9	48
91	Fluorine-18 FDG imaging in hepatocellular carcinoma using positron coincidence detection and single photon emission computed tomography. <i>Liver</i> , 2002, 22, 51-56.	0.1	29
92	A randomized study of alpha-interferon plus ribavirin for 6 months or 12 months for the treatment of chronic hepatitis C in patients with bleeding disorders. <i>Haemophilia</i> , 2002, 8, 129-135.	1.0	9
93	Detection of Hepatitis C Virus RNA and Core Protein in Keratinocytes from Patients with Cutaneous Lichen Planus and Chronic Hepatitis C. <i>Journal of Investigative Dermatology</i> , 2002, 119, 798-803.	0.3	30
94	Hepatitis infection in haemodialysis patients. <i>Nephrology</i> , 2002, 7, 101-109.	0.7	2
95	Dose-response Trial of Lactoferrin in Patients with Chronic Hepatitis C. <i>Japanese Journal of Cancer Research</i> , 2002, 93, 1063-1069.	1.7	56

#	ARTICLE	IF	CITATIONS
96	Hepatitis C Virus NS5A Protein Impairs TNF-Mediated Hepatic Apoptosis, but Not by an Anti-FAS Antibody, in Transgenic Mice. <i>Virology</i> , 2002, 294, 94-105.	1.1	105
97	Interferon inhibits progression of liver fibrosis and reduces the risk of hepatocarcinogenesis in patients with chronic hepatitis C: a retrospective multicenter analysis of 652 patients. <i>Digestive Diseases and Sciences</i> , 2002, 47, 170-176.	1.1	35
98	The hepatitis C viral NS3 protein is a processive DNA helicase with cofactor enhanced RNA unwinding. <i>EMBO Journal</i> , 2002, 21, 1168-1176.	3.5	191
99	Clinical experience of hepatic hemangioma undergoing hepatic resection. <i>Digestive Diseases and Sciences</i> , 2003, 48, 916-920.	1.1	27
100	Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. <i>Hepatology</i> , 2003, 37, 520-527.	3.6	376
101	Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients. <i>Hepatology</i> , 2003, 37, 1114-1121.	3.6	331
102	Propranolol plus placebo versus propranolol plus isosorbide-5-mononitrate in the prevention of a first variceal bleed: A double-blind RCT. <i>Hepatology</i> , 2003, 37, 1260-1266.	3.6	149
103	Nonselective β -blockers plus nitrates in portal hypertension: An open question. <i>Hepatology</i> , 2003, 37, 1254-1256.	3.6	6
104	Blood-borne viral diseases and the surgeon. <i>Current Problems in Surgery</i> , 2003, 40, 204-251.	0.6	7
105	Modulation of interferon expression by hepatitis c virus ns5a protein and human homeodomain protein ptx1. <i>Virology</i> , 2003, 306, 51-59.	1.1	18
106	Blind beta blockade. <i>Hepatology</i> , 2003, 34, 847-847.	3.6	1
108	Bile secretion in mice and men. <i>Hepatology</i> , 2001, 34, 848-850.	3.6	13
109	Schistosomiasis and antiviral treatment of chronic hepatitis C. <i>Hepatology</i> , 2003, 34, 850-850.	3.6	0
111	Inflammatory myopathy and hepatitis C in a pediatric patient: Role of liver biopsy in evaluating the severity of liver disease. <i>Hepatology</i> , 2003, 34, 851-852.	3.6	5
112	Sustained biochemical remission after interferon treatment may closely be related to the end of treatment biochemical response and associated with a lower incidence of hepatocarcinogenesis. <i>Liver International</i> , 2003, 23, 143-147.	1.9	14
113	Comparison of Doppler ultrasonography and the hepatic venous pressure gradient in assessing portal hypertension in liver cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2003, 18, 424-429.	1.4	53
114	Hepatic venous pressure gradient measurements to assess response to primary prophylaxis in patients with cirrhosis: a decision analytical study. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 17, 145-153.	1.9	47
115	Molecular viral oncology of hepatocellular carcinoma. <i>Oncogene</i> , 2003, 22, 5093-5107.	2.6	463

#	ARTICLE	IF	CITATIONS
116	Antisense overexpression of BMAL2 enhances cell proliferation. <i>Oncogene</i> , 2003, 22, 5306-5314.	2.6	27
117	18-fluorodeoxyglucose positron emission tomography in nonendocrine neoplastic disorders of the gastrointestinal tract. <i>Gastroenterology</i> , 2003, 125, 1235-1245.	0.6	30
118	Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. <i>American Journal of Gastroenterology</i> , 2003, 98, 2060-2063.	0.2	87
119	Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. <i>American Journal of Gastroenterology</i> , 2003, 98, 2060-2063.	0.2	165
120	Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. <i>Journal of Hepatology</i> , 2003, 38, 200-207.	1.8	1,287
121	Current management of portal hypertension. <i>Journal of Hepatology</i> , 2003, 38, 54-68.	1.8	245
122	Rising incidence of hepatocellular carcinoma: the role of hepatitis B and C; the impact on transplantation and outcomes. <i>Clinics in Liver Disease</i> , 2003, 7, 683-714.	1.0	16
123	Current pharmacotherapy in the management of cirrhosis: focus on the hyperdynamic circulation. <i>Expert Opinion on Pharmacotherapy</i> , 2003, 4, 625-637.	0.9	10
124	The hepatitis C virus p7 protein forms an ion channel that is inhibited by long-alkyl-chain iminosugar derivatives. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 6104-6108.	3.3	341
125	Cell Surface Expression of Major Histocompatibility Complex Class I Molecules Is Reduced in Hepatitis C Virus Subgenomic Replicon-Expressing Cells. <i>Journal of Virology</i> , 2003, 77, 11644-11650.	1.5	48
126	Measuring The Hemodynamic Response To Primary Pharmacoprophylaxis of Variceal Bleeding: A Cost-Effectiveness Analysis. <i>American Journal of Gastroenterology</i> , 2003, 98, 2742-2750.	0.2	23
127	Liver Histology and Progression of Fibrosis in Individuals With Chronic Hepatitis C and Persistently Normal Alt. <i>American Journal of Gastroenterology</i> , 2003, 98, 1588-1593.	0.2	59
128	Interferon Monotherapy for Dialysis Patients With Chronic Hepatitis C: An Analysis of The Literature on Efficacy and Safety. <i>American Journal of Gastroenterology</i> , 2003, 98, 1610-1615.	0.2	161
129	A randomized study of losartan vs propranolol: Effects on hepatic and systemic hemodynamics in cirrhotic patients. <i>Annals of Hepatology</i> , 2003, 2, 36-40.	0.6	23
130	Different Procarcinogenic Potentials of Lymphocyte Subsets in a Transgenic Mouse Model of Chronic Hepatitis B. <i>Cancer Research</i> , 2004, 64, 3326-3333.	0.4	33
131	Epidemiology, Diagnosis, and Treatment of Chronic Hepatitis C. <i>Journal of Pharmacy Practice</i> , 2004, 17, 229-238.	0.5	0
132	Two-step affinity purification of the hepatitis C virus ribonucleoprotein complex. <i>Rna</i> , 2004, 10, 321-329.	1.6	34
133	The Cost-Effectiveness of Hepatic Venous Pressure Gradient Monitoring in the Prevention of Recurrent Variceal Hemorrhage. <i>American Journal of Gastroenterology</i> , 2004, 99, 1306-1315.	0.2	35

#	ARTICLE	IF	CITATIONS
134	Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 19, 1159-1172.	1.9	148
135	The impact of immigration on the increasing incidence of hepatocellular carcinoma in the United States. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 20, 445-450.	1.9	24
136	Inflammation and necrosis promote tumour growth. <i>Nature Reviews Immunology</i> , 2004, 4, 641-648.	10.6	592
141	Effect of interferon alpha and cell cycle progression on translation mediated by the hepatitis C virus 5' untranslated region: a study using a transgenic mouse model. <i>Journal of Viral Hepatitis</i> , 2004, 11, 33-44.	1.0	4
142	Changing clinical practice with measurements of portal pressure. <i>Hepatology</i> , 2004, 39, 283-285.	3.6	48
143	Targeting portal pressure measurements: A critical reappraisal. <i>Hepatology</i> , 2004, 39, 286-290.	3.6	85
144	The hepatic venous pressure gradient: Anything worth doing should be done right. <i>Hepatology</i> , 2004, 39, 280-283.	3.6	471
145	Genetic diversity and evolution of hepatitis C virus " 15" years on. <i>Journal of General Virology</i> , 2004, 85, 3173-3188.	1.3	772
146	Acute Administration of Carvedilol is More Effective than Propranolol Plus Isosorbide-5-Mononitrate in the Reduction of Portal Pressure in Patients with Viral Cirrhosis. <i>American Journal of Gastroenterology</i> , 2004, 99, 1953-1958.	0.2	48
147	Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. <i>Gastroenterology</i> , 2004, 126, 749-755.	0.6	258
148	Caveolin and Thrombospondin Expression During Hepatocellular Carcinogenesis. <i>American Journal of Surgical Pathology</i> , 2004, 28, 357-364.	2.1	28
149	Beta Blocker Prophylaxis for Patients With Variceal Hemorrhage. <i>Journal of Clinical Gastroenterology</i> , 2005, 39, 435-440.	1.1	26
150	Serum fibrosis markers can detect large oesophageal varices with a high accuracy. <i>European Journal of Gastroenterology and Hepatology</i> , 2005, 17, 333-338.	0.8	17
151	Randomized placebo-controlled trial of interferon alpha-2b plus ribavirin with and without lactoferrin for chronic hepatitis C. <i>Hepatology Research</i> , 2005, 32, 218-223.	1.8	17
152	Multidetector CT of hepatocellular carcinoma. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2005, 19, 63-89.	1.0	18
153	Successful treatment of hepatitis C reinfection with interferon-alpha2b and ribavirin after liver transplantation. A long-term follow-up.. <i>Liver International</i> , 2005, 25, 717-722.	1.9	22
154	Disagreement between acute and chronic haemodynamic effects of nadolol in cirrhosis: a pathophysiological interpretation. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 22, 433-439.	1.9	10
155	Role of La autoantigen and polypyrimidine tract-binding protein in HCV replication. <i>Virology</i> , 2005, 335, 72-86.	1.1	80

#	ARTICLE	IF	CITATIONS
156	Differential expression of antioxidant enzymes in various hepatocellular carcinoma cell lines. <i>Journal of Cellular Biochemistry</i> , 2005, 96, 622-631.	1.2	28
157	HCV and HIV co-infection in pregnant women attending St. Camille Medical Centre in Ouagadougou (Burkina Faso). <i>Journal of Medical Virology</i> , 2005, 75, 209-212.	2.5	28
158	A Randomized Controlled Trial of β -Blockers Versus Endoscopic Band Ligation for Primary Prophylaxis: A Large Sample Size is Required to Show a Difference in Bleeding Rates. <i>Digestive Diseases and Sciences</i> , 2005, 50, 407-410.	1.1	61
159	A116C Angiotensin II Type 1 Receptor Gene Polymorphism May Predict Hemodynamic Response to Losartan in Patients with Cirrhosis and Portal Hypertension. <i>American Journal of Gastroenterology</i> , 2005, 100, 2601-2602.	0.2	1
160	Hepatitis C Virus Nonstructural Proteins Inhibit Apolipoprotein B100 Secretion. <i>Journal of Biological Chemistry</i> , 2005, 280, 39802-39808.	1.6	59
161	Regression analysis of trends in mortality from hepatocellular carcinoma in Japan, 1972-2001. <i>International Journal of Epidemiology</i> , 2005, 34, 397-402.	0.9	23
162	Hepatitis C Virus (HCV) Constitutively Activates STAT-3 via Oxidative Stress: Role of STAT-3 in HCV Replication. <i>Journal of Virology</i> , 2005, 79, 1569-1580.	1.5	145
163	A1166C Angiotensin II Type 1 Receptor Gene Polymorphism May Predict Hemodynamic Response to Losartan in Patients with Cirrhosis and Portal Hypertension. <i>American Journal of Gastroenterology</i> , 2005, 100, 636-642.	0.2	57
165	Hepatitis C Virus Stimulates the Expression of Cyclooxygenase-2 via Oxidative Stress: Role of Prostaglandin E ₂ in RNA Replication. <i>Journal of Virology</i> , 2005, 79, 9725-9734.	1.5	129
166	Development of Hepatocellular Carcinoma after Interferon Therapy in Chronic Hepatitis C. <i>Intervirology</i> , 2005, 48, 59-63.	1.2	10
167	Variceal Bleeding: Pharmacological Therapy. <i>Digestive Diseases</i> , 2005, 23, 18-29.	0.8	21
168	The Management of Portal Hypertension. <i>Clinics in Liver Disease</i> , 2005, 9, 685-713.	1.0	29
169	Replication Fitness and NS5B Drug Sensitivity of Diverse Hepatitis C Virus Isolates Characterized by Using a Transient Replication Assay. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 2059-2069.	1.4	118
170	Serum alpha-fetoprotein levels in patients with advanced hepatitis C: Results from the HALT-C Trial. <i>Journal of Hepatology</i> , 2005, 43, 434-441.	1.8	310
171	Treatment of Hepatitis C in Special Populations. <i>Clinics in Liver Disease</i> , 2005, 9, 567-577.	1.0	4
172	The Role of Functional MR Imaging in the Assessment of Tumor Response after Chemoembolization in Patients with Hepatocellular Carcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 2006, 17, 505-512.	0.2	195
173	Effect of carvedilol on portal hypertension depends on the degree of endothelial activation and inflammatory changes. <i>Scandinavian Journal of Gastroenterology</i> , 2006, 41, 1454-1463.	0.6	16
174	SAR and Mode of Action of Novel Non-Nucleoside Inhibitors of Hepatitis C NS5b RNA Polymerase. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 1034-1046.	2.9	131

#	ARTICLE	IF	CITATIONS
175	Pharmacologic Therapy of Portal Hypertension. <i>Clinics in Liver Disease</i> , 2006, 10, 563-581.	1.0	6
176	Variaciones del factor de crecimiento hepatocitario y carga viral del VHC con hemodiálisis. Comparación con terapia con el sistema de recirculación de adsorbentes moleculares (MARS). <i>Dialisis Y Trasplante</i> , 2006, 27, 37-45.	0.4	1
177	Portal Hypertension-Related Bleeding: Management of Difficult Cases. <i>Clinics in Liver Disease</i> , 2006, 10, 353-370.	1.0	6
178	American Gastroenterological Association Technical Review on the Management of Hepatitis C. <i>Gastroenterology</i> , 2006, 130, 231-264.	0.6	341
179	Beta blockers in portal hypertension. Are they really a good option?. <i>Annals of Hepatology</i> , 2006, 5, 86-91.	0.6	10
180	Comparative study between nadolol and 5-isosorbide mononitrate vs. endoscopic band ligation plus sclerotherapy in the prevention of variceal rebleeding in cirrhotic patients: a randomized controlled trial. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 24, 601-611.	1.9	59
181	De Novo Hepatocellular Carcinoma in a Patient with Chronic Hepatitis C 5 Years After Sustained Virologic Response to Interferon/Ribavirin Therapy. <i>Digestive Diseases and Sciences</i> , 2006, 51, 600-602.	1.1	10
182	Inflammation and cancer: How hot is the link?. <i>Biochemical Pharmacology</i> , 2006, 72, 1605-1621.	2.0	1,171
183	Is banding ligation for primary prevention of variceal bleeding as effective as beta-blockers, and is it safe?. <i>Hepatology</i> , 2006, 43, 196-197.	3.6	30
184	Influence of beta-2 adrenergic receptor gene polymorphism on the hemodynamic response to propranolol in patients with cirrhosis. <i>Hepatology</i> , 2006, 43, 34-41.	3.6	31
185	Outcomes, effectiveness, tolerability, and direct costs of prophylactic variceal treatments. <i>Hepatology</i> , 2006, 43, 197-198.	3.6	6
186	Seroprevalence of six different viruses among pregnant women and blood donors in rural and urban Burkina Faso: A comparative analysis. <i>Journal of Medical Virology</i> , 2006, 78, 683-692.	2.5	131
187	A Novel Ex Vivo Assay of Interferon-Based Suppression, to Predict the Outcome of Antiviral Therapy for Hepatitis C. <i>Journal of Infectious Diseases</i> , 2006, 193, 1365-1370.	1.9	4
188	Combined Interferon and Ribavirin Therapy for Chronic Hepatitis C in Taiwan. <i>Intervirology</i> , 2006, 49, 91-95.	1.2	19
189	Hepatitis C virus core protein promotes proliferation of human hepatoma cells through enhancement of transforming growth factor α expression via activation of nuclear factor- κ B. <i>Gut</i> , 2006, 55, 1801-1808.	6.1	77
190	Hepatitis Viruses, Alcohol, and Tobacco in the Etiology of Hepatocellular Carcinoma in Italy. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006, 15, 683-689.	1.1	148
191	Octreotide Enhances Portal Pressure Reduction Induced by Propranolol in Cirrhosis: A Randomized, Controlled Trial. <i>American Journal of Gastroenterology</i> , 2007, 102, 2206-2213.	0.2	11
192	Repression of Interferon Regulatory Factor 1 by Hepatitis C Virus Core Protein Results in Inhibition of Antiviral and Immunomodulatory Genes. <i>Journal of Virology</i> , 2007, 81, 202-214.	1.5	53

#	ARTICLE	IF	CITATIONS
193	Hepatitis C Virus Induces Proteolytic Cleavage of Sterol Regulatory Element Binding Proteins and Stimulates Their Phosphorylation via Oxidative Stress. <i>Journal of Virology</i> , 2007, 81, 8122-8130.	1.5	240
194	Activation of the ER stress gene gadd153 by hepatitis C virus sensitizes cells to oxidant injury. <i>Virus Research</i> , 2007, 126, 128-138.	1.1	29
196	Liver transplantation. <i>Journal of Ultrasound</i> , 2007, 10, 28-45.	0.7	8
197	Cyclooxygenase-2 (COX-2): Does it matter in patients with HCV-related liver cirrhosis?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007, 22, 1169-1171.	1.4	0
198	Hepatitis C virus genotypes and the development of hepatocellular carcinoma. <i>Journal of Digestive Diseases</i> , 2007, 8, 42-47.	0.7	10
199	Hepatitis C viral life cycle. <i>Advanced Drug Delivery Reviews</i> , 2007, 59, 1200-1212.	6.6	116
200	Protection effect of piper betel leaf extract against carbon tetrachloride-induced liver fibrosis in rats. <i>Archives of Toxicology</i> , 2007, 81, 45-55.	1.9	37
201	Molecular biology of hepatitis C virus. <i>Journal of Gastroenterology</i> , 2007, 42, 411-423.	2.3	98
202	Effect of hepatitis C virus core protein on interferon-induced antiviral genes expression and its mechanisms. <i>Virologica Sinica</i> , 2007, 22, 374-379.	1.2	1
203	Viral, host and interferon-related factors modulating the effect of interferon therapy for hepatitis C virus infection. <i>Journal of Viral Hepatitis</i> , 2001, 8, 1-18.	1.0	0
204	Hepatocellular carcinoma and other primary liver cancers in hepatitis C patients in Sweden – a low endemic country. <i>Journal of Viral Hepatitis</i> , 2008, 15, 531-537.	1.0	29
205	NS3 protein of hepatitis C virus regulates cyclooxygenase-2 expression through multiple signaling pathways. <i>Virology</i> , 2008, 371, 61-70.	1.1	36
206	Primary prophylaxis of esophageal variceal bleeding in cirrhosis. <i>Gastroenterologie Clinique Et Biologique</i> , 2008, 32, 532-540.	0.9	9
207	Variceal Bleeding. <i>Drugs</i> , 2008, 68, 2303-2324.	4.9	30
208	Management of failures of first line treatments. <i>Digestive and Liver Disease</i> , 2008, 40, 343-347.	0.4	4
209	Vasoactive factors and hemodynamic mechanisms in the pathophysiology of portal hypertension in cirrhosis. <i>Molecular Aspects of Medicine</i> , 2008, 29, 119-129.	2.7	48
210	Epidemiology of viral hepatitis infections in an area of southern Italy with high incidence rates of liver cancer. <i>European Journal of Cancer</i> , 2008, 44, 847-853.	1.3	48
211	Correlation between parametric imaging using contrast ultrasound and the histological differentiation of hepatocellular carcinoma. <i>Hepatology Research</i> , 2008, 38, 273-280.	1.8	17

#	ARTICLE	IF	CITATIONS
212	Analysis of morphological vascular changes of hepatocellular carcinoma by microflow imaging using contrast-enhanced sonography. <i>Hepatology Research</i> , 2008, 38, 790-799.	1.8	49
213	Acute administration of sildenafil enhances hepatic cyclic guanosine monophosphate production and reduces hepatic sinusoid resistance in cirrhotic patients. <i>Hepatology Research</i> , 2008, 38, 1186-1193.	1.8	26
214	Increased Levels of Galactose-Deficient Anti-Gal Immunoglobulin G in the Sera of Hepatitis C Virus-Infected Individuals with Fibrosis and Cirrhosis. <i>Journal of Virology</i> , 2008, 82, 1259-1270.	1.5	110
215	Treatment options for hepatocellular carcinoma. <i>Expert Review of Gastroenterology and Hepatology</i> , 2008, 2, 81-92.	1.4	29
216	Serum Proteomics and Biomarkers in Hepatocellular Carcinoma and Chronic Liver Disease. <i>Clinical Cancer Research</i> , 2008, 14, 470-477.	3.2	191
217	The FUSE Binding Protein Is a Cellular Factor Required for Efficient Replication of Hepatitis C Virus. <i>Journal of Virology</i> , 2008, 82, 5761-5773.	1.5	51
218	Hepatitis C virus genotype 3a infection and hepatocellular carcinoma: Pakistan experience. <i>World Journal of Gastroenterology</i> , 2009, 15, 5080.	1.4	55
219	Virological and Biochemical Features in Elderly HCV Patients with Hepatocellular Carcinoma: Amino Acid Substitutions in HCV Core Region as Predictor of Mortality after First Treatment. <i>Intervirology</i> , 2009, 52, 179-188.	1.2	6
220	Hepatitis B virus X protein shifts human hepatic transforming growth factor (TGF)- β signaling from tumor suppression to oncogenesis in early chronic hepatitis B. <i>Hepatology</i> , 2009, 49, 1203-1217.	3.6	148
221	Lack of association between genotypes and subtypes of HCV and occurrence of hepatocellular carcinoma in Egypt. <i>Journal of Medical Virology</i> , 2009, 81, 844-847.	2.5	15
222	Clinical trial: a randomized controlled study on prevention of variceal rebleeding comparing nadolol+fligation vs. hepatic venous pressure gradient-guided pharmacological therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 29, 397-408.	1.9	56
223	A liver slice culture-based <i>ex vivo</i> assay to predict the outcome of antiviral therapy for chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2009, 16, 359-366.	1.0	7
224	Lipid droplets and hepatitis C virus infection. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2009, 1791, 552-559.	1.2	83
225	Liver iron excess in patients with hepatocellular carcinoma developed on non-alcoholic steato-hepatitis. <i>Journal of Hepatology</i> , 2009, 50, 351-357.	1.8	165
226	Combination of pharmacologic and endoscopic therapy for the secondary prevention of esophageal variceal bleeding. <i>Gastrointestinal Endoscopy</i> , 2009, 70, 665-667.	0.5	1
227	Clinical Implications of Alpha-fetoprotein in Chronic Hepatitis C. <i>Journal of the Formosan Medical Association</i> , 2009, 108, 210-218.	0.8	37
228	The role of carvedilol in the management of portal hypertension. <i>European Journal of Gastroenterology and Hepatology</i> , 2010, 22, 905-911.	0.8	37
229	Hepatoprotective effects of the nitric oxide donor isosorbide-5-mononitrate alone and in combination with the natural hepatoprotectant, silymarin, on carbon tetrachloride-induced hepatic injury in rats. <i>Inflammopharmacology</i> , 2010, 18, 87-94.	1.9	14

#	ARTICLE	IF	CITATIONS
230	Duplex Doppler Ultrasound Examination of the Portal Venous System: An Emerging Novel Technique for the Estimation of Portal Vein Pressure. <i>Digestive Diseases and Sciences</i> , 2010, 55, 1230-1240.	1.1	29
231	Activation of transcription factor Nrf2 by hepatitis C virus induces the cell-survival pathway. <i>Journal of General Virology</i> , 2010, 91, 681-690.	1.3	105
232	Extract of Oregano, Coffee, Thyme, Clove, and Walnuts Inhibits NF- κ B in Monocytes and in Transgenic Reporter Mice. <i>Cancer Prevention Research</i> , 2010, 3, 653-663.	0.7	56
233	The influence of different lipid environments on the structure and function of the hepatitis C virus p7 ion channel protein. <i>Molecular Membrane Biology</i> , 2011, 28, 254-264.	2.0	18
234	Hepatitis C virus-induced furin and thrombospondin-1 activate TGF- β 1: Role of TGF- β 1 in HCV replication. <i>Virology</i> , 2011, 412, 284-296.	1.1	57
235	Simple assay based on restriction fragment length polymorphism associated with IL28B in chronic hepatitis C patients. <i>Scandinavian Journal of Gastroenterology</i> , 2011, 46, 955-961.	0.6	35
236	Progression of liver cirrhosis to HCC: an application of hidden Markov model. <i>BMC Medical Research Methodology</i> , 2011, 11, 38.	1.4	39
237	Smoking as a cofactor for the development of hepatocellular carcinoma in Egyptian patients with chronic hepatitis. <i>Egyptian Liver Journal</i> , 2011, 1, 116-122.	0.3	0
238	Detouring the Undesired Route of Helicobacter pylori-Induced Gastric Carcinogenesis. <i>Cancers</i> , 2011, 3, 3018-3028.	1.7	9
239	Management of obesity and outcomes of hepatitis C treatment. <i>Egyptian Liver Journal</i> , 2011, 1, 11-17.	0.3	0
240	Role of Toll-like receptors in liver health and disease. <i>Clinical Science</i> , 2011, 121, 415-426.	1.8	73
241	Hepatitis C Virus-Multispecific T-Cell Responses without Viremia or Seroconversion among Egyptian Health Care Workers at High Risk of Infection. <i>Vaccine Journal</i> , 2012, 19, 780-786.	3.2	18
242	Efficient Replication of Genotype 3a and 4a Hepatitis C Virus Replicons in Human Hepatoma Cells. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 5365-5373.	1.4	117
243	Hepatitis C Virus Activates Bcl-2 and MMP-2 Expression through Multiple Cellular Signaling Pathways. <i>Journal of Virology</i> , 2012, 86, 12531-12543.	1.5	29
244	Activation of the Ras/Raf/MEK Pathway Facilitates Hepatitis C Virus Replication via Attenuation of the Interferon-JAK-STAT Pathway. <i>Journal of Virology</i> , 2012, 86, 1544-1554.	1.5	64
245	Structural Analysis of Hepatitis C Virus Core-E1 Signal Peptide and Requirements for Cleavage of the Genotype 3a Signal Sequence by Signal Peptide Peptidase. <i>Journal of Virology</i> , 2012, 86, 7818-7828.	1.5	21
246	Accelerated proliferation of hepatocytes in rats with iron overload after partial hepatectomy. <i>Histochemistry and Cell Biology</i> , 2012, 138, 773-786.	0.8	14
248	Hepatitis C virus activates interleukin-1 β via caspase-1-inflammasome complex. <i>Journal of General Virology</i> , 2012, 93, 235-246.	1.3	130

#	ARTICLE	IF	CITATIONS
249	Hepatitis C viremia and genotype distribution among a sample of nonmedical prescription drug users exposed to HCV in rural Appalachia. <i>Journal of Medical Virology</i> , 2012, 84, 1376-1387.	2.5	21
250	Screening inventories to detect depression in chronic hepatitis C patients. <i>General Hospital Psychiatry</i> , 2012, 34, 40-45.	1.2	18
251	SKI-1/S1P inhibition: A promising surrogate to statins to block Hepatitis C virus replication. <i>Antiviral Research</i> , 2012, 95, 159-166.	1.9	27
252	Geographic patterns of hepatocellular carcinoma mortality with exposure to iron in groundwater in Taiwanese population: An ecological study. <i>BMC Public Health</i> , 2013, 13, 352.	1.2	11
253	Response to peginterferon-alpha 2b and ribavirin in Japanese patients with chronic hepatitis C genotype 1. <i>Hepatology International</i> , 2013, 7, 144-152.	1.9	8
254	The burden of liver disease in Europe: A review of available epidemiological data. <i>Journal of Hepatology</i> , 2013, 58, 593-608.	1.8	1,089
255	Mechanism of Hepatitis C Virus (HCV)-induced Osteopontin and Its Role in Epithelial to Mesenchymal Transition of Hepatocytes. <i>Journal of Biological Chemistry</i> , 2013, 288, 36994-37009.	1.6	43
256	Replication of Hepatitis C Virus Genotype 3a in Cultured Cells. <i>Gastroenterology</i> , 2013, 144, 56-58.e7.	0.6	45
257	Ultrasound Elastography for Fibrosis Surveillance Is Cost Effective in Patients with Chronic Hepatitis C Virus in the UK. <i>Digestive Diseases and Sciences</i> , 2013, 58, 2691-2704.	1.1	27
258	Assessment and Management of Portal Hypertension. , 2014, , 1-25.		0
259	Prediction of morbidity and mortality in patients with chronic hepatitis C by noninvasive liver fibrosis models. <i>Liver International</i> , 2014, 34, 720-727.	1.9	26
260	World Gastroenterology Organisation Global Guidelines. <i>Journal of Clinical Gastroenterology</i> , 2014, 48, 204-217.	1.1	10
261	Correlation of biochemical markers and HCV RNA titers with fibrosis stages and grades in chronic HCV-3a patients. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 788-794.	0.8	16
262	IFNL4 ss469415590 Variant Is Associated with Treatment Response in Japanese HCV Genotype 1 Infected Individuals Treated with IFN-Including Regimens. <i>International Journal of Hepatology</i> , 2014, 2014, 1-6.	0.4	9
263	Viral Carcinogenesis: Factors Inducing DNA Damage and Virus Integration. <i>Cancers</i> , 2014, 6, 2155-2186.	1.7	105
264	Incidentally Detected Hepatocellular Carcinoma in Cirrhotic Children. <i>Indian Journal of Pediatrics</i> , 2014, 81, 826-826.	0.3	5
265	Liver transplantation in a child with multifocal hepatocellular carcinoma hepatitis C and management of posttransplant viral recurrence using boceprevir. <i>Pediatric Transplantation</i> , 2014, 18, E64-8.	0.5	15
266	RacGTPase-activating protein 1 interacts with hepatitis C virus polymerase NS5B to regulate viral replication. <i>Biochemical and Biophysical Research Communications</i> , 2014, 454, 19-24.	1.0	8

#	ARTICLE	IF	CITATIONS
267	Impaired regulation of portal venous flow in response to a meal challenge as quantified by 4D flow MRI. <i>Journal of Magnetic Resonance Imaging</i> , 2015, 42, 1009-1017.	1.9	48
268	ncRNA as Diagnostics and Prognostics for Hepatocellular Carcinoma. , 2015, , 219-230.		0
270	SKI-1/S1P inhibitor PF-429242 impairs the onset of HCV infection. <i>Antiviral Research</i> , 2015, 115, 94-104.	1.9	31
271	Arachidonic acid metabolites and endothelial dysfunction of portal hypertension. <i>Prostaglandins and Other Lipid Mediators</i> , 2015, 120, 80-90.	1.0	39
272	HCV NS5A resistance-associated variants in a group of real-world Japanese patients chronically infected with HCV genotype 1b. <i>Hepatology International</i> , 2015, 9, 424-430.	1.9	30
273	Therapies: Drugs, Scopes and Transjugular Intrahepatic Portosystemic Shunt - When and How?. <i>Digestive Diseases</i> , 2015, 33, 524-533.	0.8	8
274	Osteopontin as a marker for response to pegylated interferon Alpha-2b treatment in Chronic HCV Saudi patients. <i>African Health Sciences</i> , 2017, 17, 366.	0.3	2
275	Genomic variability of within-host hepatitis C variants in acute infection. <i>Journal of Viral Hepatitis</i> , 2019, 26, 476-484.	1.0	6
277	Emerging role of human polyomaviruses 6 and 7 in human cancers. <i>Infectious Agents and Cancer</i> , 2021, 16, 35.	1.2	13
279	What to do with non-responders. , 2004, , 337-348.		2
280	What else we need. , 2004, , 349-360.		1
281	HEPATIC CIRRHOSIS. , 2009, , 505-525.		2
282	Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis. <i>Hepatology</i> , 2002, 36, 1367-1373.	3.6	113
283	Role of Hepatitis C Virus Induced Osteopontin in Epithelial to Mesenchymal Transition, Migration and Invasion of Hepatocytes. <i>PLoS ONE</i> , 2014, 9, e87464.	1.1	25
284	A case of hepatocellular carcinoma in a patient with hemophilia a associated with human immunodeficiency virus infection.. <i>Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical)</i> Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 17		1
285	Pathophysiology of Portal Hypertension. <i>Medical Radiology</i> , 2000, , 1-14.	0.0	0
286	Lebervenenverschlussdruck. , 2003, , 290-297.		0
287	Bildgebende Verfahren. , 2003, , 232-289.		0

#	ARTICLE	IF	CITATIONS
289	Measurement of Portal Pressure. , 2010, , 511-517.		0
290	Assessment and Management of Portal Hypertension. , 2015, , 3667-3686.		0
291	Pharmacologic Therapy for Management of Esophageal Varices. , 2005, , 199-219.		0
293	Management of Portal Hypertension and Biliary Problems Prior to Transplantation. , 0, , 43-65.		0